Atrinsic (NASDAQ:PTIX) Stock Price Down 0.8% – What’s Next?

Shares of Atrinsic Inc. (NASDAQ:PTIXGet Free Report) dropped 0.8% during mid-day trading on Tuesday . The company traded as low as $1.13 and last traded at $1.19. Approximately 26,153 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 31,222 shares. The stock had previously closed at $1.20.

Atrinsic Trading Down 4.8%

The firm has a market capitalization of $1.81 million, a price-to-earnings ratio of -0.13 and a beta of 1.77. The company’s 50 day moving average is $0.41 and its 200-day moving average is $0.51.

Atrinsic Company Profile

(Get Free Report)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.

Further Reading

Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.